A Phase 3 interventional study of Acetylsalicylic acid and Apixaban in Aortic Stenosis, sponsored by Oslo University Hospital. Completed at 3 sites in Norway. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by Oslo University Hospital · Phase 3, Interventional, and Prevention
ACASA-TAVI is a pragmatic randomized controlled trial assessing the value of anticoagulation therapy versus the standard antiplatelet therapy after transcatheter aortic valve implantation in patients with aortic stenosis. The trial will assess the efficacy of direct oral anticoagulation (DOAC) therapy compared to the standard single antiplatelet therapy to prevent degeneration of the valve and its safety in co-primary endpoints with blinded endpoint adjudication. The effect of DOAC therapy on hard clinical outcomes will be assessed during long-term follow-up.
Aortic stenosis is a highly prevalent valvular disease and an important cause of morbidity and mortality in the elderly population. Transcatheter aortic valve implantation (TAVI) is an effective intervention in patients with severe aortic stenosis and low surgical risk. The procedure is highly effective, safe, and widely implemented. Current recommendations support transcatheter treatment of younger patients, including patients from 65 years of age with low surgical risk. This practice increases the importance of long-term valve maintenance.
Observational data have suggested that early signs of valve degeneration (i.e. hypo-attenuated leaflet thickening/thrombosis/reduced leaflet motion) are associated with an increased risk of embolic events. This is an increasing problem with emerging indications in younger populations. Because both ischemic and bleeding complications after TAVI can be life-threatening, it is important to establish the optimal anti-thrombotic treatment regime. Use of oral anticoagulation after implantation for bioprosthetic valves have been associated with resolved valve degeneration and possible favourable clinical effects.
The current practice guidelines recommend that oral anticoagulation may be considered for 3 months after open surgical bioprosthetic valve implantation. Patients with an independent indication for oral anticoagulation (i.e. atrial fibrillation or venous thromboembolism) are recommended to continue this treatment lifelong, but there is no recommendation for oral anticoagulation following TAVI in patients without other indications. In patients without indication for oral anticoagulation, the use of double anti-platelet therapy for 3-6 months following TAVI is recommended. However, single anti-platelet therapy with acetylsalicylic acid (ASA) without clopidogrel has been reported to improve bleeding outcomes and a composite of bleeding and ischemic outcomes. The effect of on oral anticoagulation-based treatment strategy compared to the standard single anti-platelet treatment strategy for valve maintenance after TAVI is unknown.
Increased anti-thrombotic treatment intensity may come at the cost of increased bleeding risk. Dual anti-platelet therapy and combination therapy with anticoagulation and anti-platelet therapy have both been associated with unfavourable outcomes. Combined anti-platelet and anti-coagulation treatment has been shown to reduce valve degeneration at the cost of increased bleeding. Conversely, single anti-platelet therapy and anti-coagulation with a direct oral anti-coagulant (DOAC) have been associated with similar bleeding risk. Bleeding rates in patients treated with anti-coagulation after TAVI have been reported to be slightly higher than in patients treated with ASA after TAVI, but patients with conventional indications for anti-coagulation have higher baseline bleeding risk than those without such indications. Therefore, the risk of bleeding in patients treated with DOAC or ASA following TAVI may be similar, but no randomized trials have been performed.
ACASA-TAVI will include 360 patients > 65 years and \< 80 years of age who have undergone successful TAVI and have no conventional indication for DOAC in a prospective randomized open-label blinded-endpoint (PROBE) study. The intervention arm will be 12 month therapy with an anti-Xa type DOAC (without antiplatelet therapy) and the active control arm will be standard dose ASA. After 12 months, the intervention group will be switched to ASA maintenance. All patients will undergo clinical assessment, cardiac CT and echocardiography at 12 months with blinded endpoint adjudication by an independent committee.
Outcome measures will comply with the Valve Academic Research Consortium 3 (VARC-3) consensus, and are described in detail in the protocol. The co-primary endpoints at 12 months, hypo-attenuated leaflet thickening (HALT) and safety composite, must both be met for the trial to declare success.
The effect of the DOAC therapy on long-term major adverse cardiovascular events (MACE) will be assessed after 5 years and 10 years.
985 studies on the registry are indexed under Aortic Valve Stenosis; 283 are open to participants now.
This study's enrollment of 360 is above the median of 120 across 525 interventional studies indexed under Aortic Valve Stenosis.
Browse Aortic Valve Stenosis studies →Oslo University Hospital is the lead sponsor of 810 studies on the registry; 148 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients in the active control arm will receive 75 mg acetylsalicylic acid once daily indefinitely.
Drug: Acetylsalicylic acid
Patients in the experimental arm will receive an anti Xa-type DOAC (apixaban, rivaroxaban or edoxaban) in approved therapeutic dose for 12 months. The choice of DOAC agent will be made by the treating clinician after discussion with the patient. After 12 months, these patients will abort DOAC therapy. Acetylsalicylic acid, 75 mg once daily will be started after DOAC discontinuation and continued indefinitely.
Drug: Apixaban · Drug: Rivaroxaban · Drug: Edoxaban
Acetylsalicylic acid 75 mg once daily is the current standard-of-care in TAVI patients without other indications for anticoagulation therapy.
Also known as: B01A C06
Standard dose apixaban will be one of the options for the patients in the experimental arm.
Also known as: B01A F02
Standard dose rivaroxaban will be one of the options for the patients in the experimental arm.
Also known as: B01A F01
Standard dose edoxaban will be one of the options for the patients in the experimental arm.
Also known as: B01A F03
Hypo-attenuated leaflet thickening
First co-primary endpoint. The presence of hypo-attenuated leaflet thickening on dedicated cardiac CT after 12 months will be registered by a blinded expert reader. Intention-to-treat, superiority.
Time frame: 12 months
Safety composite - Incidence of Treatment Emergent Adverse Clinical Outcome
Second co-primary outcome. Composite of VARC-3 bleeding events, thromboembolic events (myocardial infarction or stroke) and all-cause mortality. Per-protocol, non-inferiority.
Time frame: 12 months
Major adverse cardiovascular events (MACE)
Primary outcome during long-term follow-up. The rate of the composite of Cardiac death, Aortic valve re-intervention, Stroke, Myocardial infarction, Heart failure hospitalization and Major, life-threatening, or disabling bleeding.
Time frame: 5 years
Major adverse cardiovascular events (MACE)
Primary outcome during long-term follow-up. The rate of the composite of Cardiac death, Aortic valve re-intervention, Stroke, Myocardial infarction, Heart failure hospitalization and Major, life-threatening, or disabling bleeding.
Time frame: 10 years
Clinical efficacy
First hierarchical secondary outcome. Composite of of Freedom from all-cause mortality, Freedom from all stroke, Freedom from hospitalization for procedure- or valve-related causes, Freedom from KCCQ overall summary score \<45 or decline from baseline of \>10 points. Intention-to-treat, superiority.
Time frame: 12 months
Safety composite, superiority
Second hierarchical secondary outcome. Composite of VARC-3 bleeding events, thromboembolic events (myocardial infarction or stroke) and all-cause mortality. Same endpoint as second co-primary outcome, but intention-to-treat, superiority.
Time frame: 12 months
Thromboembolic events
Third hierarchical secondary outcome. Composite of myocardial infarction or stroke of any cause. Intention-to-treat population.
Time frame: 12 months
Bleeding events
Fourth hierarchical secondary outcome. Bleeding events according to VARC-3 definitions. Intention-to-treat population.
Time frame: 12 months
All-cause mortality
Fifth hierarchical secondary outcome. Intention-to-treat population.
Time frame: 12 months
The number of adverse events
First secondary safety endpoint. Safety population.
Time frame: 12 months
The number of serious adverse events
Second secondary safety endpoint. Safety population.
Time frame: 12 months
Life-threatening or disabling bleeding
Third secondary safety endpoint. Safety population. VARC-3 definition.
Time frame: 12 months
Major bleeding
Fourth secondary safety endpoint. Safety population. VARC-3 definition.
Time frame: 12 months
Minor bleeding
Fifth secondary safety endpoint. Safety population. VARC-3 definition.
Time frame: 12 months
CT signs of valve degeneration
Exploratory outcome. Any evidence of reduced leaflet mobility, hypo-attenuated leaflet thickening or thrombus.
Time frame: 12 months
Echocardiographic signs of valve degeneration
Exploratory outcome. Change in transaortic pressure gradient assessed by echocardiography.
Time frame: 12 months
Cardiac function
Exploratory outcome. Change in left ventricular global longitudinal strain assessed by echocardiography.
Time frame: 12 months
Non-procedure-related life-threatening or disabling bleeding
Exploratory outcome. VARC-3 definition.
Time frame: 12 months
Number of major adverse clinical events
Exploratory outcome. Defined as stroke or transient ischemic attack of any cause, myocardial infarction, re-intervention on the aortic valve, death (cardiac, all-cause, non-cardiac) and heart failure hospitalization
Time frame: 12 months
Troponin T
Exploratory outcome. Assessment of blood samples.
Time frame: 12 months
N-terminal pro-B-type natriuretic peptide
Exploratory outcome. Assessment of blood samples.
Time frame: 12 months
Infective endocarditis
Exploratory outcome. Definition by Duke criteria.
Time frame: 12 months
Change in quality of life - Kansas City Cardiomyopathy Questionnaire
Exploratory outcome. Assessed by change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score (score 0-100, Higher value indicates better quality of life).
Time frame: 12 months
Cognitive function
Exploratory outcome. Assessed by change in the Mini-cog score
Time frame: 12 months
Clinical efficacy
Composite of of Freedom from all-cause mortality, Freedom from all stroke, Freedom from hospitalization for procedure- or valve-related causes, Freedom from KCCQ overall summary score \<45 or decline from baseline of \>10 points. Intention-to-treat, superiority.
Time frame: 5 years
All-cause mortality
Fifth hierarchical secondary outcome. Intention-to-treat population.
Time frame: 5 years
Echocardiographic signs of valve degeneration
Exploratory outcome. Change in transaortic pressure gradient assessed by echocardiography.
Time frame: 5 years
Cardiac function
Exploratory outcome. Change in left ventricular global longitudinal strain assessed by echocardiography.
Time frame: 5 years
N-terminal pro-B-type natriuretic peptide
Exploratory outcome. Assessment of blood samples.
Time frame: 5 years
Troponin T
Exploratory outcome. Assessment of blood samples.
Time frame: 5 years
Individual components of MACE
Exploratory outcome. Assessment of the individual components of MACE (the primary outcome at long-term follow-up).
Time frame: 5 years
Change in quality of life - Kansas City Cardiomyopathy Questionnaire
Exploratory outcome. Assessed by change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score (score 0-100, Higher value indicates better quality of life).
Time frame: 5 years
Cognitive function
Exploratory outcome. Assessed by change in the Mini-cog score
Time frame: 5 years
Infective endocarditis
Exploratory outcome. Definition by Duke criteria.
Time frame: 5 years
Clinical efficacy
Composite of of Freedom from all-cause mortality, Freedom from all stroke, Freedom from hospitalization for procedure- or valve-related causes, Freedom from KCCQ overall summary score \<45 or decline from baseline of \>10 points. Intention-to-treat, superiority.
Time frame: 10 years
All-cause mortality
Fifth hierarchical secondary outcome. Intention-to-treat population.
Time frame: 10 years
Echocardiographic signs of valve degeneration
Exploratory outcome. Change in transaortic pressure gradient assessed by echocardiography.
Time frame: 10 years
Cardiac function
Exploratory outcome. Change in left ventricular global longitudinal strain assessed by echocardiography.
Time frame: 10 years
N-terminal pro-B-type natriuretic peptide
Exploratory outcome. Assessment of blood samples.
Time frame: 10 years
Troponin T
Exploratory outcome. Assessment of blood samples.
Time frame: 10 years
Individual components of MACE
Exploratory outcome. Assessment of the individual components of MACE (the primary outcome at long-term follow-up).
Time frame: 10 years
Change in quality of life - Kansas City Cardiomyopathy Questionnaire
Exploratory outcome. Assessed by change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score (score 0-100, Higher value indicates better quality of life).
Time frame: 10 years
Cognitive function
Exploratory outcome. Assessed by change in the Mini-cog score
Time frame: 10 years
Infective endocarditis
Exploratory outcome. Definition by Duke criteria.
Time frame: 10 years
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — The application to share IPD is pending with the ethical committee.
Supporting information: Study protocol, Sap, Icf, Csr, Analytic code
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oslo University Hospital